Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 8Thoracic 3Lymphoid 2Gynecologic 2Gastrointestinal 2Dermatologic 2Genitourinary 1CNS 1Breast 1

Conditions

Glioblastoma 3Ovarian Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1

Interventions

Docetaxel 7Radiotherapy 6Filgrastim 6Cisplatin 4Peripheral Blood Stem Cell Transplantation 3Chemotherapy, Adjuvant 3Carboplatin 3selpercatinib 2sargramostim 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2Nivolumab 2Gemcitabine 2Etoposide 2Drug Therapy 2Doxorubicin 2Capecitabine 2Biopsy 2Acupuncture Therapy 2vocimagene amiretrorepvec 1vandetanib 1ulixertinib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tanespimycin 1spartalizumab 1pentetreotide 1pazopanib 1oncogene protein E7, Human papillomavirus type 16 1oblimersen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × epacadostat × CNS × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡